Recent developments highlight Zevra's ongoing operational execution, clinical data presentations, and financial performance updates.

• Zevra Therapeutics reported net income of $19.2 million and basic EPS of $0.31 for Q3 2026, with strong liquidity metrics as of September 30, 2026 [S2].
• The company presented long-term data on MIPLYFFA for Niemann-Pick Disease at SSIEM 2026, supporting clinical efficacy [N2].
• Zevra's Q2 2026 earnings call highlighted operational progress and revenue surpassing prior periods [N2][N3].
• The company announced a partnership with GeneDx to enhance genetic testing programs, potentially aiding patient identification [N6].
• Zevra turned profitable in 2025 driven by strong uptake of MIPLYFFA for Niemann-Pick Disease Type C [N6].
• Recent quarterly earnings calls and reports provide detailed operational and financial updates, reflecting ongoing business activities [N1][N2][N3].

Zevra has established a profitable commercial presence with MIPLYFFA for Niemann-Pick Disease Type C, supported by positive clinical and real-world data. The company maintains strong liquidity and has demonstrated operational execution through recent earnings reports. Its participation in government pricing programs ensures access to federal healthcare markets. Strategic partnerships, such as with GeneDx for genetic testing, may enhance patient identification and market penetration. Continued regulatory compliance and data security efforts support sustainable operations.

Zevra faces risks related to regulatory compliance with complex government pricing and rebate programs, which could result in penalties or financial liabilities if not properly managed. Cybersecurity threats pose risks to sensitive clinical and proprietary data, potentially disrupting operations or triggering regulatory actions. The niche market for Niemann-Pick Disease Type C limits revenue diversification. Any adverse regulatory decisions or challenges in clinical development could impact product uptake. The company's financial performance depends on continued market acceptance and effective management of operational risks.

Zevra Therapeutics' moat is primarily based on its specialized focus on rare diseases, particularly Niemann-Pick Disease Type C, and its marketed product MIPLYFFA, which addresses a niche patient population with limited treatment options. The company's clinical data and real-world evidence support product efficacy, which may contribute to competitive differentiation. Regulatory approvals and participation in government pricing programs create barriers to entry for competitors. However, the rarity of the disease and regulatory complexities also pose challenges to rapid market expansion. The company's partnerships and ongoing clinical development efforts further support its position in this specialized therapeutic area.

• Regulatory Compliance Risks: Zevra participates in multiple U.S. government healthcare pricing programs such as MDRP, 340B, VA FSS, and Tricare, which impose complex pricing, reporting, and rebate obligations. Failure to comply may lead to penalties, sanctions, or termination from these programs, adversely affecting financial results [S1].
• Cybersecurity and Data Privacy Risks: The company handles sensitive personal and proprietary information and faces risks from cybersecurity breaches, data loss, and disruptions. Such events could lead to regulatory penalties, litigation, reputational damage, and operational interruptions [S1].
• Market Concentration Risk: Zevra's commercial success is concentrated on MIPLYFFA for Niemann-Pick Disease Type C, a rare disease with a limited patient population, which may constrain revenue growth and diversification.

• Zevra Therapeutics, Inc. is a biopharmaceutical company focused on treatments for rare diseases, including Niemann-Pick Disease Type C (NPC).
• The company has a marketed product named MIPLYFFA, used for treating Niemann-Pick Disease Type C.
• Zevra turned profitable in 2025 driven by strong uptake of MIPLYFFA for NPC.
• The company reported net income of $19.2 million for the quarter ended September 30, 2026, with basic earnings per share of $0.31 and diluted EPS of $0.26, as per its 10-Q filing dated November 3, 2026.
• As of September 30, 2026, Zevra held $122.1 million in cash and cash equivalents and had current assets of $225.8 million against current liabilities of $41.4 million, resulting in a current ratio of 5.46 and a cash ratio of 2.98.
• Zevra participates in various U.S. government healthcare pricing and rebate programs including the Medicaid Drug Rebate Program (MDRP), 340B drug pricing program, VA Federal Supply Schedule pricing program, and Tricare Retail Pharmacy program, which impose regulatory compliance and pricing obligations.
• The company faces regulatory risks related to compliance with government pricing programs and potential penalties or sanctions for non-compliance.
• Zevra is subject to cybersecurity and data privacy risks, including potential breaches that could impact clinical trial data, regulatory scrutiny, and financial costs.
• The company has presented positive clinical data and real-world evidence supporting MIPLYFFA's efficacy in NPC patients.
• Zevra has engaged in partnerships, such as with GeneDx for a new genetic testing program.
• Recent quarterly earnings calls and reports indicate ongoing operational updates and financial performance disclosures.
• There have been no material changes to the risk factors described in the 2025 Annual Report and subsequent quarterly filings as of November 2026.